Cite
APA Citation
Wu, J., Song, Y., Chen, X., Lin, T., Cao, J., Liu, Y., Zhao, Y., Jin, J., Huang, H., Hu, J., Luo, J., Zhang, L., Xue, H., Zhang, Q., Wang, W., Chen, C., Feng, J., & Zhu, J. (2022). camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study. International journal of cancer, 150(6), 984–992. http://access.bl.uk/ark:/81055/vdc_100148849939.0x00005f